Dissemin is shutting down on January 1st, 2025

Published in

Elsevier, Molecular Immunology, 1(47), p. 19-27

DOI: 10.1016/j.molimm.2009.01.007

Links

Tools

Export citation

Search in Google Scholar

Tumor Necrosis Factor and the consequences of its ablation in vivo

Journal article published in 2009 by G. A. Efimov, A. A. Kruglov, S. V. Tillib, D. V. Kuprash ORCID, S. A. Nedospasov
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Although TNF has been discovered due to anti-tumor activity, its physiological functions are different. Current knowledge places TNF downstream of many receptors of innate immunity, implying its primary role in host defense and inflammation. When overproduced systemically or locally, TNF may exert deleterious effects on the organism. Anti-TNF therapy is highly efficient in several autoimmune and inflammatory diseases. However, due to TNF unique beneficial functions in immune system, such therapy cannot be entirely free of adverse effects. We review the current status of the field with the focus on drugs and strategies used for TNF ablation in vivo.